Clopidogrel thiolactone
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 564073

CAS#: 1147350-75-1

Description: Clopidogrel thiolactone, also known as 2-Oxoclopidogrel, is a metabolite of Clopidogrel.

Chemical Structure

img
Clopidogrel thiolactone
CAS# 1147350-75-1
Instruction

Theoretical Analysis

MedKoo Cat#: 564073
Name: Clopidogrel thiolactone
CAS#: 1147350-75-1
Chemical Formula: C16H16ClNO3S
Exact Mass: 337.05
Molecular Weight: 337.820
Elemental Analysis: C, 56.89; H, 4.77; Cl, 10.49; N, 4.15; O, 14.21; S, 9.49

Price and Availability

Size Price Availability Quantity
5mg USD 560 2 Weeks
Bulk inquiry

Synonym: 2-Oxo-clopidogrel; Clopidogrel thiolactone; 2-Oxoclopidogrel

IUPAC/Chemical Name: (2S)-Methyl 2-(2-chlorophenyl)-2-(2-oxo-7,7a-dihydrothieno[3,2-c]pyridin-5(2H,4H,6H)-yl)acetate

InChi Key: JBSAZVIMJUOBNB-WUJWULDRSA-N

InChi Code: InChI=1S/C16H16ClNO3S/c1-21-16(20)15(11-4-2-3-5-12(11)17)18-7-6-13-10(9-18)8-14(19)22-13/h2-5,8,13,15H,6-7,9H2,1H3/t13?,15-/m0/s1

SMILES Code: O=C(OC)[C@H](C1=CC=CC=C1Cl)N2CCC3C(C2)=CC(S3)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 337.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Xie HG, Jia YM, Tai T, Ji JZ. Overcoming Clopidogrel Resistance: Three Promising Novel Antiplatelet Drugs Developed in China. J Cardiovasc Pharmacol. 2017 Dec;70(6):356-361. doi: 10.1097/FJC.0000000000000529. PMID: 28817486.


2: Nishiya Y, Hagihara K, Ito T, Tajima M, Miura S, Kurihara A, Farid NA, Ikeda T. Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel. Drug Metab Dispos. 2009 Mar;37(3):589-93. doi: 10.1124/dmd.108.022988. Epub 2008 Dec 1. PMID: 19047469.


3: Zhu Y, Zhou J. In vitro biotransformation studies of 2-oxo-clopidogrel: multiple thiolactone ring-opening pathways further attenuate prodrug activation. Chem Res Toxicol. 2013 Jan 18;26(1):179-90. doi: 10.1021/tx300460k. Epub 2012 Dec 28. PMID: 23249383.


4: Dansette PM, Levent D, Hessani A, Bertho G, Mansuy D. Thiolactone sulfoxides as new reactive metabolites acting as bis-electrophiles: implication in clopidogrel and prasugrel bioactivation. Chem Res Toxicol. 2013 May 20;26(5):794-802. doi: 10.1021/tx400083b. Epub 2013 Apr 9. PMID: 23527615.


5: Shan J, Zhang B, Zhu Y, Jiao B, Zheng W, Qi X, Gong Y, Yuan F, Lv F, Sun H. Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent. J Med Chem. 2012 Apr 12;55(7):3342-52. doi: 10.1021/jm300038c. Epub 2012 Apr 2. PMID: 22428882.


6: Hagihara K, Kazui M, Kurihara A, Yoshiike M, Honda K, Okazaki O, Farid NA, Ikeda T. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos. 2009 Nov;37(11):2145-52. doi: 10.1124/dmd.109.028498. Epub 2009 Aug 24. PMID: 19704027.


7: Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2010 Feb;50(2):126-42. doi: 10.1177/0091270009343005. Epub 2009 Nov 30. Erratum in: J Clin Pharmacol. 2010 Apr;50(4):483. PMID: 19948947.


8: Dansette PM, Rosi J, Bertho G, Mansuy D. Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem Res Toxicol. 2012 Feb 20;25(2):348-56. doi: 10.1021/tx2004085. Epub 2011 Dec 1. PMID: 22103858.


9: Hagihara K, Kazui M, Ikenaga H, Nanba T, Fusegawa K, Takahashi M, Kurihara A, Okazaki O, Farid NA, Ikeda T. Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. Xenobiotica. 2009 Mar;39(3):218-26. doi: 10.1080/00498250802650077. PMID: 19280520.


10: Chen J, Wang MZ. Potent and Orally Bioavailable Antiplatelet Agent, PLD-301, with the Potential of Overcoming Clopidogrel Resistance. Lett Drug Des Discov. 2016 Mar;13(3):250-254. doi: 10.2174/1570180812666150730221941. PMID: 27594816; PMCID: PMC4997949.


11: Schrör K, Siller-Matula JM, Huber K. Pharmacokinetic basis of the antiplatelet action of prasugrel. Fundam Clin Pharmacol. 2012 Feb;26(1):39-46. doi: 10.1111/j.1472-8206.2011.00986.x. Epub 2011 Sep 5. PMID: 21895761.


12: Qiu Z, Li N, Wang X, Tian F, Liu Q, Song L, Fan Z, Lu Y, Chen X. Pharmacokinetics of vicagrel, a promising analog of clopidogrel, in rats and beagle dogs. J Pharm Sci. 2013 Feb;102(2):741-9. doi: 10.1002/jps.23394. Epub 2012 Nov 28. PMID: 23192851.


13: Dansette PM, Levent D, Hessani A, Mansuy D. Bioactivation of clopidogrel and prasugrel: factors determining the stereochemistry of the thiol metabolite double bond. Chem Res Toxicol. 2015 Jun 15;28(6):1338-45. doi: 10.1021/acs.chemrestox.5b00133. Epub 2015 May 21. PMID: 25970225.


14: Zhang H, Amunugama H, Ney S, Cooper N, Hollenberg PF. Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme. Mol Pharmacol. 2011 Nov;80(5):839-47. doi: 10.1124/mol.111.073783. Epub 2011 Aug 23. PMID: 21862689; PMCID: PMC3198913.


15: Chen CH, Yang JC, Uang YS, Lin CJ. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel. Biopharm Drug Dispos. 2012 Jul;33(5):278-83. doi: 10.1002/bdd.1795. Epub 2012 Jun 29. PMID: 22623337.


16: Nishiya Y, Hagihara K, Kurihara A, Okudaira N, Farid NA, Okazaki O, Ikeda T. Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel. Xenobiotica. 2009 Nov;39(11):836-43. doi: 10.3109/00498250903191427. PMID: 19845434.


17: Kiebist J, Schmidtke KU, Schramm M, König R, Quint S, Kohlmann J, Zuhse R, Ullrich R, Hofrichter M, Scheibner K. Biocatalytic Syntheses of Antiplatelet Metabolites of the Thienopyridines Clopidogrel and Prasugrel Using Fungal Peroxygenases. J Fungi (Basel). 2021 Sep 13;7(9):752. doi: 10.3390/jof7090752. PMID: 34575790; PMCID: PMC8470877.


18: Hagihara K, Kazui M, Kurihara A, Ikeda T, Izumi T. Glutaredoxin is involved in the formation of the pharmacologically active metabolite of clopidogrel from its GSH conjugate. Drug Metab Dispos. 2012 Sep;40(9):1854-9. doi: 10.1124/dmd.112.045914. Epub 2012 Jun 25. PMID: 22733806.


19: Zhu T, Wu Y, Li XM, Jia YM, Zhou H, Jiang LP, Tai T, Mi QY, Ji JZ, Xie HG. Vicagrel is hydrolyzed by Raf kinase inhibitor protein in human intestine. Biopharm Drug Dispos. 2022 Dec;43(6):247-254. doi: 10.1002/bdd.2340. Epub 2022 Dec 23. PMID: 36519186.


20: Ernest CS 2nd, Small DS, Rohatagi S, Salazar DE, Wallentin L, Winters KJ, Wrishko RE. Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):593-618. doi: 10.1007/s10928-008-9103-7. Epub 2008 Nov 21. PMID: 19023649.